Drug
Tivozanib
Tivozanib: highest development phase Phase 3, developed by Aveo Pharmaceuticals, United Therapeutics. 19 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Aveo Pharmaceuticals, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tivozanib NCT04987203 | Phase 3 | Renal Cell Carcinoma |
| Tivozanib hydrochloride NCT02627963 | Phase 3 | Carcinoma, Renal Cell |
| Tivozanib NCT01076010 | Phase 3 | Advanced Renal Cell Carcinoma |
| tivozanib (AV-951) NCT01030783 | Phase 3 | Advanced Renal Cell Carcinoma |
| Tivozanib NCT01673386 | Phase 2 | Metastatic Renal Cell Carcinoma |
| Tivozanib NCT01297244 | Phase 2 | Renal Cell Carcinoma |
| Tivozanib NCT01478594 | Phase 2 | Colorectal Cancer |
| tivozanib NCT01782313 | Phase 2 | Recurrent Adult Soft Tissue Sarcoma |
| Tivozanib NCT06053658 | Phase 2 | Renal Cell Carcinoma |
| Tivozanib NCT01972516 | Phase 2 | Ovarian Cancer |
| Tivozanib Hydrochloride NCT01745367 | Phase 2 | Triple Negative Breast Cancer |
| Tivozanib (1mg) NCT01835223 | Phase 1/2 | Advanced Adult Hepatocellular Carcinoma |
| Tivozanib NCT03970616 | Phase 1/2 | Hepatocellular Carcinoma |
| Tivozanib NCT03136627 | Phase 1/2 | Carcinoma, Renal Cell |
| tivozanib NCT01316848 | Phase 1 | Food Effect of Tivozanib in Health Subjects |
| Tivozanib (AV-951) NCT00826878 | Phase 1 | Carcinoma, Non-Small-Cell Lung |
| tivozanib NCT01210846 | Phase 1 | Advanced Solid Tumors |
| Tivozanib NCT01363804 | Phase 1 | Healthy |
| tivozanib NCT01769885 | Not Applicable | Stage II Renal Cell Cancer |
Latest
No recent events.
Follow Tivozanib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.